In underdeveloped countries, diabetic neuropathy (DN) is one of the leading causes of blindness. Currently, one out of every five diabetic patients may be diagnosed with DN. In clinical practise and clinical trials, assessing DN has proven to be complex and challenging. Unfortunately, there is no one treatment for neuropathic alterations or pain relief that can be used to avoid or reverse them. Intensive glucose control, risk factor management, and genetically configuration are the three main therapy options for diabetic neuropathy. Amitriptyline and duloxetine have now been discovered as effective pain relievers in DN. However, there is an increasing need for research to analyse the most effective medications and combinations for the treatment of DN in order to maximise pain alleviation and improve quality of life. Nav antagonists, N-type calcium channel blockers, NGF antibodies, and angiotensin II type 2 receptor antagonists are all viable options for DN treatment. Modifying risk factors, genetics, and treatment of DN are all discussed in this topic.
Author(S) Details
D. Nagasamy Venkatesh
Department of Pharmaceutics, JSS College of Pharmacy, Ooty – 643 001, Tamil Nadu, India.
S. D. Shanmugakumar
Jyothishmathi Institute of Pharmaceutical Sciences Thimmapur, Karimnagar, Telanagana – 505481, India.
View Book:- https://stm.bookpi.org/CAPRD-V5/article/view/4947
No comments:
Post a Comment